The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.10
Bid: 43.10
Ask: 46.90
Change: 1.30 (2.97%)
Spread: 3.80 (8.817%)
Open: 43.10
High: 43.10
Low: 43.10
Prev. Close: 43.70
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

13 Jan 2021 07:00

RNS Number : 4664L
Benchmark Holdings PLC
13 January 2021
 

13 January 2021

Benchmark Holdings plc

("Benchmark" or "the Company")

Payment of contingent consideration following achievement of milestones

 

Issue of Equity

 

Benchmark (AIM: BMK), the aquaculture health, nutrition and genetics business, announces that further to the acquisition of aquaculture breeding programmes centred on shrimp from Centro de Investigación de la Acuicultura de Colombia Ceniacua on 11 August 2016, $450,000 of contingent consideration is payable following the satisfaction of specified operational milestones (the "Contingent Consideration").

At the Company's discretion, the Contingent Consideration is payable in ordinary shares in the Company using an agreed formula. The Company has therefore issued 536,272 Ordinary Shares of 0.1p each in the capital of the Company (the "New Ordinary Shares").

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and trading will commence at 8:00am on 18 January 2021. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 668,927,771. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Trond Williksen, CEO, commented:

 

"The payment of the contingent consideration is a reflection of the success of our shrimp genetics operations since the acquisition was made. Through a team of leading geneticists, we successfully expanded our genetics business into shrimp and developed a Specified Pathogen Resistant SPR shrimp which will be rolled out in Asia in the coming year.

 

"Specialist genetics are a significant driver of sustainable production. The introduction of SPR shrimp will help improve sustainability in shrimp production and is an important growth vector for Benchmark, as we remain focused on becoming a profitable, cash generative Group."

 

 Enquiries

For further information, please contact:

 

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

 

Septima Maguire, CFO

 

Ivonne Cantu, Investor Relations

 

 

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

 

 

 

MHP Communications

Tel: 020 3128 8742

Katie Hunt, Reg Hoare, Alistair de Kare-Silver, Charlie Protheroe

benchmark@mhpc.com

 

 

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFEFUEEFSEFF
Date   Source Headline
20th Dec 20197:00 amRNSQ4 Results
20th Dec 20197:00 amRNSFull Year Results
4th Dec 20197:00 amRNSDirectorate Change
29th Nov 20197:00 amRNSQ4 and FY Trading Update & Notice of Results
29th Nov 20197:00 amRNSTotal Voting Rights
11th Nov 20197:00 amRNSChief Financial Officer Appointment Update
8th Nov 20197:00 amRNSInvesting in a sustainable future for aquaculture
31st Oct 20197:00 amRNSTotal Voting Rights
28th Oct 20197:00 amRNSUpdate on dissolution of JV with AquaChile
25th Oct 20198:10 amRNSHolding(s) in Company
25th Oct 20197:00 amRNSHolding(s) in Company
11th Oct 201911:15 amRNSDIRECTOR DEALINGS
30th Sep 20197:00 amRNSTotal Voting Rights
27th Sep 20197:00 amRNSDIRECTOR DEALINGS
20th Sep 20197:00 amRNSBlock listing Interim Review
17th Sep 20197:00 amRNSHolding(s) in Company
16th Sep 20197:00 amRNSDIRECTOR DEALINGS
16th Sep 20197:00 amRNSDIRECTOR DEALINGS
12th Sep 20194:25 pmRNSHolding(s) in Company
12th Sep 201911:15 amRNSHolding(s) in Company
11th Sep 20197:00 amRNSUpdate on commercial licensing deals
30th Aug 20197:00 amRNSTotal Voting Rights
19th Aug 20197:00 amRNSDirectorate Change
16th Aug 20193:55 pmRNSDetails of Investor Call
14th Aug 20197:00 amRNSDirectorate Change
12th Aug 20197:00 amRNSQ3 Trading Update
31st Jul 20191:15 pmRNSReplacement: Total Voting Rights
31st Jul 20197:00 amRNSTotal Voting Rights
11th Jul 20197:00 amRNSGenetics Breakthrough in Tilapia
9th Jul 20197:00 amRNSDirectorate Change
2nd Jul 20193:49 pmRNSHolding(s) in Company
2nd Jul 20197:00 amRNSHolding(s) in Company
28th Jun 20194:41 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20192:05 pmRNSSecond Price Monitoring Extn
28th Jun 20192:00 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSTotal Voting Rights
25th Jun 20197:00 amRNSInterim Results
13th Jun 20198:00 amRNSPlacement of a new senior secured bond issue
10th Jun 20197:00 amRNSUpdate on Joint Venture with AquaChile
3rd Jun 20197:00 amRNSTrading Update and Investor Meetings
31st May 20197:00 amRNSTotal Voting Rights
29th May 20197:00 amRNSUpdate on Joint Venture with AquaChile
30th Apr 20197:00 amRNSTotal Voting Rights
29th Mar 20192:25 pmRNSReplacement: Total Voting Rights
29th Mar 20197:00 amRNSTotal Voting Rights
21st Mar 20197:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
14th Mar 201912:21 pmRNSResult of AGM
28th Feb 20197:00 amRNSTotal Voting Rights
20th Feb 20197:00 amRNSAppointment of Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.